INTRODUCTION
A ccording to the American Thyroid Association (ATA), preparation with recombinant human TSH (rhTSH) stimulation is an acceptable alternative to thyroid hormone withdrawal (THW) for ablation of thyroid remnants with radioactive iodine (RAI) in patients with papillary thyroid carcinoma (PTC) at low or intermediate risk with lymph node (LN) metastases restricted to the central neck compartment (N1a) and discrete/microscopic metastases (1) . This is considered a "strong recommendation" and "moderate-quality evidence" (1) . Even more favorable, the European Thyroid Association (ETA) (2) and many authors (3, 4) consider rhTSH to be the "preparation of choice" for these patients.
In contrast, in the absence of comorbidities that prevent THW, in intermediate-risk patients with LN metastases not limited to the central neck compartment (N1b) or clinically apparent/macroscopic metastases (cN1), rhTSH stimulation "may be considered" an alternative to adjuvant RAI treatment (1) . Apparently, ATA does not consider rhTSH to be at the same level as THW (5) . This observation is supported by the fact that this recommendation is considered a "weak recommendation" and "low-quality evidence" (1) . In agreement, in the absence of any clinical contraindication, ETA (2) and other authors (3, 4) also consider THW the most indicated preparation for patients with macroscopic LN metastases.
Indeed, ATA calls attention to the fact that, among the randomized studies comparing the efficacy of ablation with RAI preceded by rhTSH versus THW, few investigations included N1 patients (1). More importantly, almost all patients had exclusive central neck compartment metastasis (N1a) and the studies only reported the short-term outcomes (1) . There was only one retrospective study that included a significant number of cN1b patients (6) . This scenario has not changed since the publication of the ATA guidelines (1) .
Obviously, more investigations, especially long-term studies, evaluating the efficacy of rhTSH specifically in these patients (cN1b) are necessary and desirable. The objective of this study was to compare the short-and long-term outcomes of adjuvant RAI therapy preceded by rhTSH versus THW specifically in patients with PTC and clinically apparent LN metastases not limited to the central neck compartment (cN1b).
SUBJECTS AND METHODS
The study was approved by the Research Ethics Committee of our institution.
Patients
Patients with PTC consecutively seen at our institution from 2006 to 2014 and undergoing total thyroidectomy with apparently complete tumor resection were first selected. Only patients with LN metastases detected by preoperative US or during intraoperative inspection by the surgeon [clinical N1 (cN1)] were submitted to LN dissection. A total of 206 patients had LN metastases outside the central neck compartment detected by preoperative US or during intraoperative inspection by the surgeon (cN1b). Eighteen patients with incomplete tumor resection, extensive extrathyroid invasion (pT4) and distant metastases known before RAI (detected by clinical examination or simple chest X-ray), who are classified as high risk by ATA (1), were excluded.
Therapy with levothyroxine (L-T4) was initiated immediately after surgery and the dose was adjusted to maintain TSH < 2 mIU/l. Neck US was performed 96 to 180 days (median 140 days) after thyroidectomy. Ten patients with positive neck US were excluded. Finally, 178 patients had US scans that showed no anomalies.
These patients were treated with 30-100 mCi (1.1-3.7 GBq) RAI and composed the sample of this study.
Adjuvant therapy with RAI
The patients were submitted to adjuvant RAI therapy after THW for 4 weeks or administration of rhTSH and of a low-iodine diet for 10 days prior to the procedure. Anterior and posterior whole-body images were obtained 7 days after therapy with RAI (RxWBS).
Initial assessment after RAI therapy
The patients were evaluated 12 months after RAI therapy by the measurement of nonstimulated thyroglobulin (Tg), antithyroglobulin antibodies (TgAb), and neck US. In the case of patients with ectopic uptake on initial RxWBS, in addition to US, diagnostic WBS (DxWBS) and computed tomography (CT) were performed to exclude persistent disease. Imaging methods other than US [neck, chest and mediastinal CT, fluorodeoxyglucosepositron emission tomography (FDG-PET)/CT] were performed if nonstimulated Tg levels ≥ 1 ng/mL.
Follow-up
The patients were maintained on TSH < 0.5 mIU/l and were followed up by clinical examination, measurement of nonstimulated Tg and TgAb at intervals of 6-12 months, and annual neck US. Imaging methods other than US were performed when nonstimulated Tg converted to levels ≥ 1 ng/mL. The time of follow-up ranged from 18 to 118 months (median 66 months).
Outcomes
The outcomes were: (i) rate of excellent response to therapy, i.e., nonstimulated Tg ≤ 0.2 ng/mL, with negative TgAb and negative neck US, 1 year after RAI (1-4); (ii) structural disease 1 year after RAI; (iii) structural or biochemical (nonstimulated Tg > 1 ng/mL, with increment) recurrence during follow-up, and (iv) percentage of patients without disease in the last assessment, i.e., nonstimulated Tg < 1 ng/mL and no evidence of structural disease. In the case of patients with metastases detected by RxWBS who required a new cycle of RAI to treat persistent disease, the preparation (rhTSH or THW) was always the same in all cycles.
Imaging methods
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Arch Endocrinol Metab. 2017;61/2 for power Doppler evaluation. All suspected lesions apparent on the scans (7, 8) were evaluated by US-guided fine-needle aspiration biopsy. DxWBS was obtained 3 days after RAI administration (185 MBq) with rhTSH stimulation. Contrast-enhanced CT was performed on 5-mm sequential sections. FDG-PET/CT was carried out after stimulation with rhTSH. All images were analyzed by experienced Radiology or Nuclear Medicine specialists.
Apparent disease was defined based on the results of the imaging methods, cytology or histology, and/ or unequivocal ectopic uptake (excluding false-positive results) on RxWBS or FDG-PET/CT. 
Statistical analysis
Means were compared between groups by the Student t-test or the nonparametric Mann-Whitney U test. Fisher's exact test or chi-squared test was used to detect differences in the proportion of cases. A p value of less than 0.05 was considered to be significant.
RESULTS
Characteristics of the patients
The characteristics of the patients studied are shown in Table 1 . The patients were classified as intermediate risk according to ATA (1). The two groups (rhTSH and THW) were similar in terms of sex, age, tumor stage, serum TSH immediately before the administration of 131 I, RAI activity, frequency of metastases on initial RxWBS, and time of follow-up.
Initial assessment after adjuvant therapy with RAI
When evaluated 12 months after therapy with RAI, an excellent response to initial therapy was achieved in 149 patients (83.7%). Structural disease was detected in 8 patients (4.5%). Five of these patients had metastases on initial RxWBS and persistent disease (mediastinal in 2, pulmonary in 2, cervical and pulmonary in 1) and three had no metastases on initial RxWBS (in these cases, FDG-PET revealed bone metastases in 1, cervical in 1, and cervical and mediastinal in 1). The rates of excellent response and structural disease 1 year after initial therapy were similar in the rhTSH and THW groups ( Table 2) .
Twenty-one patients (11.8%) had elevated Tg in the absence of apparent disease detected by the imaging methods: 15 had indeterminate response [8/87 patients (9.2%) in the THW group and 7/91 patients (7.7%) in the rhTSH group (p = 0.8)] and 6 had incomplete biochemical response [2/87 patients (2.3%) in the THW group and 4/91 patients (4.4%) in the rhTSH group (p = 0.7)]. I. b Uptake outside the thyroid bed and non-physiological: cervical (n = 3), mediastinal (n = 2), pulmonary (n = 2), cervical and pulmonary (n = 1), and cervical and mediastinal (n = 1).
Late follow-up
During follow-up, 8/170 patients (4.7%) without structural disease 1 year after RAI relapsed (Table 2) . Six patients had structural disease (neck metastases detected by US in 3 and by FDG-PET in 1, and pulmonary rhTSH and radioiodine Arch Endocrinol Metab. 2017;61/2 metastases detected by CT and RxWBS in 1 and by CT and FDG-PET in 1). In 2 patients, nonstimulated Tg increased (> 1 ng/mL) in the absence of apparent disease detected by the imaging methods (US, CT, and FDG-PET). The recurrence rate was the same in the two groups (Table 2) . of disease did not differ between the two groups ( Table 2) . There was no case of death due to the tumor.
DISCUSSION
Specifically in patients with PTC and clinical apparent lymph node metastases not limited to the central neck compartment (cN1b), when THW is not contraindicated, preparation with rhTSH for adjuvant RAI therapy is not yet considered to be at the same level as THW by ATA (1), ETA (2) and other authors (3, 4) . According to ATA, few randomized studies comparing the efficacy of ablation with rhTSH versus THW included N1 patients, almost all patients had exclusive central neck compartment metastasis (N1a), and only the shortterm outcomes were reported (1). There was only one retrospective study that included a significant number of cN1b patients (6) .
The present study included a significant number of patients (approximately 90 in each group) and not only evaluated the outcomes 1 year after RAI but also the longterm evolution of the patients. The median follow-up time was longer than 5 years. In this respect, it is known that 80% of recurrences occur in these first years (9) (10) (11) . It should be noted that in the present study patients with elevated Tg without structural disease did not receive a new cycle of RAI. Consequently, the results of the last assessment of patients without persistent or recurrent disease reflect the effect of initial therapy. The study was prospective and the selection criteria were pre-defined. However, one limitation of our study is that the patients were not randomized, with the choice of the preparation being defined based on the access of the patient to rhTSH. Nevertheless, the groups were similar in terms of sex, age, tumor stage, TSH concentrations before RAI, RAI activity, and time of follow-up. In addition, the patients were followed up at the same institution and were submitted to the same follow-up protocol.
In the present study, rhTSH was equally effective as THW as a preparation for adjuvant therapy with RAI. The two preparations were also similar in the series of Hugo and cols. (6) including 183 N1b patients, but the efficacy of therapy was much lower than that found in the present series despite the use of higher RAI activities. In the study of Hugo and cols. (6), part of the cN1b patients exhibited additional findings [incomplete tumor resection, distant metastases, and extensive extrathyroid invasion (pT4)] and the efficacy of RAI was indeed higher when these patients were excluded 
Last assessment
All 162 patients without structural disease 1 year after RAI, who developed no recurrence and who were not submitted to any additional therapy, continued to have nonstimulated Tg < 1 ng/mL (≤ 0.2 ng/mL in 153), negative TgAb, and neck US showing no anomalies in the last assessment. The two patients in whom Tg increased (biochemical recurrence) continued to have elevated Tg in the absence of structural disease identified until the last assessment.
In the last assessment, among the 14 patients with structural disease detected after initial therapy and who had undergone new surgery (LN dissection) and/or had been treated with RAI and/or external radiotherapy and maintained under TSH suppression, 7 patients achieved remission, structural disease persisted in 6 patients, and one patient had elevated Tg in the absence of structural disease. Thus, in the last assessment, the percentage of patients without evidence rhTSH and radioiodine Arch Endocrinol Metab. 2017;61/2 and only intermediate-risk patients were considered. As supporting data, in a subsequent publication of the same group, the response rate of intermediate-risk cN1b patients to initial therapy was approximately 85% (12) . In another series involving N1bM0 patients, the recurrence rate ranged from 15-20% (13) (14) (15) (16) (17) (18) , while this rate was approximately 10% in the present series. We attribute this apparent difference to the fact that the present study excluded cN1b patients who additionally exhibited incomplete tumor resection and extensive extrathyroid invasion (pT4) [high risk according to ATA (1)]. In addition, postoperative US (before RAI) was obtained for all patients of the present series as currently recommended (1) and patients with positive US were excluded. If this imaging method were not performed, these cases would have probably been detected subsequently, which would increase the rate of persistent or recurrent disease. Other smaller series that compared rhTSH versus THW for adjuvant RAI therapy included N1b patients, but the number of these patients was only about 10 in each group (19) (20) (21) (22) .
One limitation of this study was the lack of Tg results before RAI. However, specifically in these cN1b patients, negative Tg and TgAb do not exclude the need for RAI. First, ATA (1) and ETA (2) continue to recommend adjuvant therapy with RAI for cN1b patients, as do many authors (3, 4) . Second, in previous series, persistent disease was detected by RxWBS in 7% of N1 patients with stimulated Tg < 1 ng/mL and negative US (23) and in 12% of patients with undetectable nonstimulated Tg (24) . It is possible that, if these patients had not received RAI, the lesions seen on RxWBS would have progressed to apparent disease during follow-up. Third, not every microscopic residual disease is apparent on RxWBS and yet can progress to structural disease. Destruction of these microscopic tumor foci, preventing recurrence, is exactly the rational of adjuvant therapy with RAI (1). In addition, the two groups (rhTSH and THW) were similar in terms of initial characteristics and patients were operated on by the same surgeons. The proportion of patients with negative pre-RAI Tg is therefore expected to be the same. Thus, the conclusion of the efficacy of adjuvant therapy with RAI in cN1b patients preceded by rhTSH or THW, which was the objective of the study, most likely would not be modified by this information.
Our results show that in patients with cN1b PTC without distant metastases and with complete tumor resection (including postoperative US without metastases), preparation with rhTSH was equally effective as THW for adjuvant therapy with RAI in the short-and long-term. Thus, rhTSH could be considered equal to THW also in these patients.
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